These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 31182225)

  • 1. Long-term CIN3+ risk of HPV positive women after triage with FAM19A4/miR124-2 methylation analysis.
    Dick S; Kremer WW; De Strooper LMA; Lissenberg-Witte BI; Steenbergen RDM; Meijer CJLM; Berkhof J; Heideman DAM
    Gynecol Oncol; 2019 Aug; 154(2):368-373. PubMed ID: 31182225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FAM19A4/miR124-2 methylation analysis as a triage test for HPV-positive women: cross-sectional and longitudinal data from a Dutch screening cohort.
    Vink FJ; Lissenberg-Witte BI; Meijer CJLM; Berkhof J; van Kemenade FJ; Siebers AG; Steenbergen RDM; Bleeker MCG; Heideman DAM
    Clin Microbiol Infect; 2021 Jan; 27(1):125.e1-125.e6. PubMed ID: 32222459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of molecular markers for cervical screening of women living with HIV in South Africa.
    Kremer WW; van Zummeren M; Breytenbach E; Richter KL; Steenbergen RDM; Meijer CJLM; Dreyer G
    AIDS; 2019 Nov; 33(13):2035-2042. PubMed ID: 31385866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cervical cancer risk in HPV-positive women after a negative FAM19A4/mir124-2 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow-up.
    De Strooper LMA; Berkhof J; Steenbergen RDM; Lissenberg-Witte BI; Snijders PJF; Meijer CJLM; Heideman DAM
    Int J Cancer; 2018 Sep; 143(6):1541-1548. PubMed ID: 29663363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-stratification of HPV-positive women with low-grade cytology by FAM19A4/miR124-2 methylation and HPV genotyping.
    Dick S; Vink FJ; Heideman DAM; Lissenberg-Witte BI; Meijer CJLM; Berkhof J
    Br J Cancer; 2022 Feb; 126(2):259-264. PubMed ID: 34743198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylation markers FAM19A4 and miR124-2 as triage strategy for primary human papillomavirus screen positive women: A large European multicenter study.
    Bonde J; Floore A; Ejegod D; Vink FJ; Hesselink A; van de Ven PM; Valenčak AO; Pedersen H; Doorn S; Quint WG; Petry KU; Poljak M; Stanczuk G; Cuschieri K; de Sanjosé S; Bleeker M; Berkhof J; Meijer CJLM; Heideman DAM
    Int J Cancer; 2021 Jan; 148(2):396-405. PubMed ID: 32997803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the FAM19A4/mir124-2 DNA methylation test for both lavage- and brush-based self-samples to detect cervical (pre)cancer in HPV-positive women.
    De Strooper LMA; Verhoef VMJ; Berkhof J; Hesselink AT; de Bruin HME; van Kemenade FJ; Bosgraaf RP; Bekkers RLM; Massuger LFAG; Melchers WJG; Steenbergen RDM; Snijders PJF; Meijer CJLM; Heideman DAM
    Gynecol Oncol; 2016 May; 141(2):341-347. PubMed ID: 26921784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing the performance of FAM19A4 methylation analysis, cytology and HPV16/18 genotyping for the detection of cervical (pre)cancer in high-risk HPV-positive women of a gynecologic outpatient population (COMETH study).
    Luttmer R; De Strooper LM; Berkhof J; Snijders PJ; Dijkstra MG; Uijterwaal MH; Steenbergen RD; van Kemenade FJ; Rozendaal L; Helmerhorst TJ; Verheijen RH; Ter Harmsel WA; Van Baal WM; Graziosi PG; Quint WG; Heideman DA; Meijer CJ
    Int J Cancer; 2016 Feb; 138(4):992-1002. PubMed ID: 26317579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining hrHPV genotypes in cervical intraepithelial neoplasia by laser capture microdissection supports reflex triage of self-samples using HPV16/18 and FAM19A4/miR124-2 methylation.
    Leeman A; Ebisch RMF; Kasius A; Bosgraaf RP; Jenkins D; van de Sandt MM; de Strooper LMA; Heideman DAM; Snijders PJF; Massuger LFAG; Bekkers RLM; Meijer CJLM; van Kemenade FJ; Quint WGV; Melchers WJG
    Gynecol Oncol; 2018 Nov; 151(2):311-318. PubMed ID: 30219239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FAM19A4/miR124-2 Methylation Testing and Human Papillomavirus (HPV) 16/18 Genotyping in HPV-Positive Women Under the Age of 30 Years.
    Vink FJ; Meijer CJLM; Hesselink AT; Floore AN; Lissenberg-Witte BI; Bonde JH; Pedersen H; Cuschieri K; Bhatia R; Poljak M; Oštrbenk Valenčak A; Hillemanns P; Quint WGV; Del Pino M; Kenter GG; Steenbergen RDM; Heideman DAM; Bleeker MCG
    Clin Infect Dis; 2023 Feb; 76(3):e827-e834. PubMed ID: 35686306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Regression of High-Grade Cervical Intraepithelial Neoplasia Is Associated With Absence of
    Kremer WW; Dick S; Heideman DAM; Steenbergen RDM; Bleeker MCG; Verhoeve HR; van Baal WM; van Trommel N; Kenter GG; Meijer CJLM; Berkhof J
    J Clin Oncol; 2022 Sep; 40(26):3037-3046. PubMed ID: 35512257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reliable identification of women with CIN3+ using hrHPV genotyping and methylation markers in a cytology-screened referral population.
    Leeman A; Del Pino M; Marimon L; Torné A; Ordi J; Ter Harmsel B; Meijer CJLM; Jenkins D; Van Kemenade FJ; Quint WGV
    Int J Cancer; 2019 Jan; 144(1):160-168. PubMed ID: 30098013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methylation testing with S5 for triage of high-risk HPV positive women.
    Adcock R; Nedjai B; Lorincz AT; Scibior-Bentkowska D; Banwait R; Torrez-Martinez N; Robertson M; Cuzick J; Wheeler CM;
    Int J Cancer; 2022 Oct; 151(7):993-1004. PubMed ID: 35477862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping.
    Hernández-López R; Lorincz AT; Torres-Ibarra L; Reuter C; Scibior-Bentkowska D; Warman R; Nedjai B; Mendiola-Pastrana I; León-Maldonado L; Rivera-Paredez B; Ramírez-Palacios P; Lazcano-Ponce E; Cuzick J; Salmerón J;
    Clin Epigenetics; 2019 Oct; 11(1):140. PubMed ID: 31606044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
    Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
    BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cervix cytology samples revealed increased methylation of the human markers FAM19A4/miR124-2 up to 8 years before adenocarcinoma.
    Lindroth Y; Pedersen L; Alssamaray J; Berglund T; Sundqvist A; Borgfeldt C; Forslund O
    Acta Obstet Gynecol Scand; 2024 Feb; 103(2):378-386. PubMed ID: 37964497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of partial HPV16/18 genotyping in stratifying HPV-positive women attending routine cervical cancer screening: a population-based cohort study.
    Gori S; Battagello J; Gustinucci D; Campari C; Zorzi M; Frayle H; Passamonti B; Sartori G; Bulletti S; Fodero C; Cesarini E; Faggiano R; Del Mistro A
    BJOG; 2021 Jul; 128(8):1353-1362. PubMed ID: 33326680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
    Gilham C; Sargent A; Kitchener HC; Peto J
    Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of FAM19A4/miR124-2 methylation performance in the management of CIN3 diagnosed pregnant women.
    Hampl M; Hesselink AT; Meijer CJLM; Denecke A; Einhorn I; Reinecke-Luethge A; Geppert CI; Jentschke M; ; Petry KU; Hillemanns P
    Int J Cancer; 2022 Nov; 151(9):1578-1585. PubMed ID: 35666529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.